Germ cell tumors and particularly seminomas reflect the epigenomic features of their parental primordial germ cells (PGCs), including genomic DNA hypomethylation and expression of pluripotent cell markers. Because the DNA hypomethylation might be a result of TET dioxygenase activity, we examined expression of TET1-3 enzymes and the level of their product, 5-hydroxymethylcytosine (5hmC), in a panel of histologically characterized seminomas and non-seminomatous germ cell tumors. Expression of TET dioxygenase mRNAs was quantified by real-time PCR. TET1 expression and the level of 5hmC were examined immunohistochemically. Quantitative assessment of 5-methylcytosine (5mC) and 5hmC levels was done by the liquid chromatography-mass spectroscopy technique. We found highly increased expression of TET1 dioxygenase in most seminomas and strong TET1 staining in seminoma cells. Isocitrate dehydrogenase 1 and 2 mutations were not detected, suggesting the enzymatic activity of TET1. The levels of 5mC and 5hmC in seminomas were found decreased in comparison to non-seminomatous germ cell tumors and healthy testicular tissue. We propose that TET1 expression should be studied as a potential marker of seminomas and mixed germ cell tumors and we suggest that elevated expression of TET dioxygenase enzymes is associated with the maintenance of low DNA methylation levels in seminomas. This "anti-methylator" phenotype of seminomas is in contrast to the CpG island methylator phenotype (CIMP) observed in a fraction of tumors of various types.
hypermethylated CpG islands surrounding the promoter regions of several genes, 11 a phenomenon referred to as CpG island methylator phenotype (CIMP). Importantly, the level of CIMP can be used for classification of colorectal cancers 12 and correlates with the disease prognosis, 13 and response to chemotherapy. 14 Similarly, CIMP cases are frequently found in glioblastoma 15 and to a lesser extent in other types of tumors.
Hypermethylation in CIMP tumors can be caused by increased DNA methyltransferase (DNMT) activity; however, the most common change in epigenome modulators is the decreased expression of TET dioxygenases. TET1, 2, and 3 are members of α-ketoglutarate-dependent enzymes with a capacity to initiate active DNA demethylation by converting 5-methylcytosine (5mC)
to 5-hydroxymethylcytosine (5hmC), 16 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). 17 5caC is further excised by thymine DNA glycosylase and using the DNA base excision repair mechanism replaced by an unmodified cytosine. 18 Consequently, decreased expression of TET genes could eventually lead to DNA hypermethylation. 19 Indeed, reduced TET expression has been found in various types of cancer and correlates with reduction of 5hmC. [20] [21] [22] Similarly, mutations in TET2 or reduced TET2 expression and the corresponding decrease of 5hmC were found in acute myeloid leukemia. [23] [24] [25] Because of the strict dependence of TET dioxygenases on α-ketoglutarate, mutations of isocitrate dehydrogenase genes 1 and 2 (IDH1, 2) leading to production of TET-inhibiting oncometabolite 2-hydroxyglutarate have been found as an alternative to TET reduction in many tumors [26] [27] [28] [29] and are regarded as a part of CIMP.
In contrast to CIMP tumors, seminomas have been reported to be hypomethylated, [30] [31] [32] reflecting the germ line origin of seminoma. GCNIS can give rise to seminomas or non-seminomas. [33] [34] [35] Nonseminoma develops when a GCNIS cell or a seminoma cell becomes reprogramed to a pluripotent embryonal carcinoma cell that can subsequently differentiate into teratomas, yolk-sac tumors, or choriocarcinomas. 35 Molecular mechanisms of this progression remain to be understood; there are however, epigenetic and gene expression correlates. From the epigenetic point of view, GCNIS and seminomas retain the hypomethylated state of DNA, embryonal carcinoma have an intermediate level of 5mC, and yolk sac tumors, teratomas and choriocarcinomas have been reported to have the highest levels of DNA methylation. 36 Differential expression of DNMTs was reported between seminomas and nonseminomas. 37 Consistently with the germ line origin, the PGCs, GCNIS, seminoma cells, and embryonal carcinoma cells express pluripotency markers, including OCT4, NANOG, and SALL4. [38] [39] [40] [41] [42] [43] [44] Similar to high TET1 and TET2 expression in mouse ES cells, 45 high TET1 and TET2 expression was also detected in migratory PGCs, see ref. 19 for review. Gonadal PGCs undergo extensive DNA demethylation with a possible role of TET1 and 5hmC in this epigenetic reprograming. 19, 46 However, the expression of TET enzymes in testicular GCTs has been sparsely documented. Elevated expression of TET1 has been reported in cell lines derived from a seminoma or embryonal carcinoma 31 ; the same study also demonstrated that the majority of seminomas contain low global 5mC and 5hmC levels in comparison to non-seminomas. Interestingly, the elevated TET1
mRNA expression in seminoma cell line TCam-2 did not induce any significant increase in the 5hmC levels. Increased levels of 5mC/5hmC appeared only after induced transition of the TCam-2 cells into embryonal carcinoma-like state. 31 Similarly, GCNIS were found to contain low levels of 5mC/5hmC, and GCNIS together with different testicular GCTs expressed TET1 and TET2 mRNAs. 32 Thus, to further investigate the epigenetic reprograming in the development of seminomas and non-seminomas, we examined the TET family expression and levels of 5mC and 5hmC in seminomas and nonseminoma GCTs in tissue sections.
| MATERIALS AND METHODS

| Ethics statement
The study was conducted in accordance with the principles of WMA 
| Immunohistochemistry analysis of TET1 and 5hmC
Five micrometer thick paraffin sections were subjected to IHC analysis.
IHC labeling was performed after heat-induced epitope retrieval in Supplementary Table S1 .
Products obtained after the PCRs were inserted into the pGEM-T Easy vector (Promega) and sequenced with an M13 universal RV primer.
| Liquid chromatography-mass spectrometry quantification of 5mC and 5hmC
Genomic DNAs of selected tumor samples and tumor-matched controls were used for quantitative analysis of 5mC and 5hmC. The analysis by combined liquid chromatography-mass spectrometry was performed as described recently. 49 Briefly, 2′-deoxycytidine (dC), 2′-deoxyguanosine (dG), and 5-hydroxymethyl-2′-deoxycytidine were purchased from Berry and Associates; C5-methyl-2′-deoxycytidine (5mC) was purchased from R.I. Chemicals. Genomic DNA was digested to nucleosides for a minimum of 8 h at 37°C using a digestion enzymatic mixture containing per sample 1 U benzonase, 0.5 mU phosphodiesterase I, 200 mU alkaline phosphatase in 20 mM Tris-HCl pH 7.9, and 4 mM MgCl 2 . Enzymes were precipitated using acetonitrile overnight at −20°C. All the points of the standard curve were spiked with the same matrix (digestion mix) as the samples. The nucleosides were separated on an Agilent RRHD Eclipse Plus C18 2.1 × 100 mm 1.8 u column by using the HPLC 1290 system (Agilent, Santa Clara, CA) and analyzed using an Agilent 6490 triple quadrupole mass spectrometer. To calculate the concentrations of individual nucleosides, standard curves representing the peak response of known amounts of synthetic nucleosides were generated and used to convert the peak-area values in the samples to corresponding concentrations.
The threshold for peak detection is a signal-to-noise (calculated with a peak-to-peak method) above 10. Accuracy of the measurement has been monitored by the use of the internally heavy labelled nucleoside standards. Similarly to, 31 we observed that TET1 mRNA expression in the TCam-2 cell line was dependent on the cell density. Therefore, we always 
| siRNA transfection
| Statistical analysis
The significance of intergroup differences was evaluated by the Mann-Whitney test and the P-values were denoted as follows: * <0.05, ** <0.01, *** <0.001, **** <0.0001.
3 | RESULTS
| The set of human malignant tumor samples
To carry out this study, we collected a set of cancer biopsies from adult patients with testicular cancer (Supplementary Table S2 ). The set included 29 pure seminoma samples and 18 non-seminomas, specifically 13 mixed malignant testicular GCTs, two pure embryonal carcinomas, two pure teratomas, and one pure yolk sac tumor. When possible, tumor-matched controls were collected from the adjacent tissue not affected macroscopically with the GCT (Supplementary Table S2 ). The set also contained seven samples of the testes not diagnosed with the GCTs (termed non-GCT controls throughout the text). Our collection further included tumors of non-germ cell origin, specifically three Hodgkin lymphomas and five non Hodgkin lymphomas, and six endometrial carcinomas (Supplementary Table S2 ).
Human GCTs originate from transformed PGCs and were shown to express pluripotent cell markers. 35 To illustrate the PGC features in our GCT set, we quantified the expression of pluripotent cell markers in a selected subset of seminomas and non-seminomas. mRNA levels of OCT4, NANOG, and SALL4 were assessed by qRT-PCR. Seminomas revealed significantly higher expression of OCT4, NANOG, and SALL4 mRNAs than the seminoma-matched controls (P < 0.01, P < 0.001, P < 0.001, respectively, Supplementary Fig. S1A-C) . Expression of OCT4 and SALL4 pluripotency markers in the seminomas was also significantly elevated in comparison with the non-GCT controls (P < 0.01 and P < 0.05, respectively, Supplementary Fig. S1A,C) . In contrast, only OCT4 mRNA was significantly elevated in the nonseminomas in comparison with the non-GCT controls (P < 0.05, Supplementary Fig. S1C ), and none of the analyzed markers were elevated in the non-seminomas in comparison with the nonseminoma-matched controls. Further, expression of SALL4 in the seminomas was significantly higher than in the non-seminomas (P < 0.05, Supplementary Fig. S1C ).
Collectively, the analysis confirmed a broad pluripotent phenotype of assembled seminomas. In contrast, only the OCT4 pluripotency marker showed elevated mRNA levels in the non-seminomas.
| High level of TET1 mRNA expression in seminomas
TET proteins were shown to have important roles in PGCs. 46, 50 Therefore, we explored the TET1 mRNA levels in seminomas and nonseminomas by qRT-PCR using the total RNA isolated from the biopsies including both germ and differentiated somatic cells. TET1 mRNA levels were highly elevated in seminomas in comparison with the seminoma-matched controls (P < 0.0001), non-GCT control testes (P < 0.0001, Fig. 1 ), and non-seminomas as a whole (P < 0.05, Supplementary Fig. S2A ). Non-seminomas displayed significantly higher levels of TET1 mRNA only in comparison with the non-GCT controls (P < 0.001, Fig. 1 ). Two embryonal carcinoma samples showed variable levels of TET1 mRNA, but TET1 mRNA expression was low in two analyzed teratoma samples as well as in one yolk sac tumor sample (Fig. 1) . The seminoma-derived cell line TCam-2 expressed high levels of TET1 mRNA (Fig. 1) . Interestingly, the choriocarcinoma-derived BeWo cell line also overexpressed TET1 mRNA, although the expression was lower than in TCam-2 cells (Fig. 1 ). Lymphomas and endometrial carcinomas also displayed low levels of TET1 mRNA (Fig. 1 ). Differentiated tissues, placenta and PBMCs showed low levels of TET1 mRNA comparable with the non-GCT control testes (Fig. 1) . In summary, our data demonstrated the highest overexpression of TET1 mRNA in seminomas, and to a lesser extent, in non-seminomas.
| IHC analysis of TET1 in GCT
To confirm the TET1 overexpression at the protein level and explore its distribution pattern in different cell types, we examined TET1 by IHC staining in tissue sections of selected GCTs. The staining was evaluated for the whole tissue sections (Fig. 2 , Supplementary Table S3 and Fig. S3,   S4 ) and in distinct components of mixed GCTs ( Supplementary Fig. S3 ).
We observed stronger nuclear and weak to moderate granular cytoplasmic staining of tumor cells. Gonocytes, Leydig, and Sertoli cells stained weakly during normal spermatogenesis, whereas most interstitial elements in non-tumor tissue were negative ( Fig. 2A, left panel) .
Weaker to moderate TET1 positivity was observed in germ cell neoplasia in situ (GCNIS indicated by an arrow in Fig. 2A, right panel) .
Six out of eight pure seminomas analyzed (T1, T2, T4, T7, T18, T22 in Supplementary Table S2 ) displayed strong to moderate TET1 positivity (Supplementary Table S3 ), whereas two seminomas (T3, T15) showed weak positivity (representative microphotographs in Table S3 ). Moderate intensity of TET1 staining was observed in the epithelial structures of a teratoma sample (T46) and in the yolk sac tumor (T47, Supplementary Table S3 and Fig. S3C,D) . The high intensity of TET1 staining in seminomas and non-seminomas is further illustrated by elevated H-score ( Supplementary Fig. S4 ). Intriguingly, we observed not only nuclear but also granular cytoplasmic TET1 staining in tumor cells. The specificity of the anti-TET1 antibody ab121587 (Abcam, Cambridge, UK) was confirmed by using the second anti-TET1 antibody, ab191698 (Abcam). We observed identical staining with both antibodies (representative microphotographs are shown in Fig. 2C, lower panels) . Importantly, the tumormatched controls for all seminomas, mixed GCTs, embryonal 
| TET2 and TET3 expression in seminomas and mixed GCTs
All three TET enzymes oxidize 5mC to 5hmC and reverse DNA methylation. Therefore, in addition to TET1, we analyzed TET2 and TET3 mRNA expression in our set of tumors using qRT-PCR. Overall, the detected TET2 and TET3 mRNA levels were lower than TET1 mRNA levels (Fig. 3) . As in the case of TET1, the seminomas displayed higher levels of TET2 and TET3 mRNAs than seminomamatched controls (P < 0.001 and P < 0.0001, respectively), and non-GCT controls (P < 0.0001 in both cases, Fig. 3A,B) . The expression of TET2 mRNA in the mixed GCTs was significantly higher than in the non-GCT controls (P < 0.01, Fig. 3A ). TET3 mRNA levels in the mixed GCTs were significantly higher than in the tumor-matched controls and in the non-GCT controls (P < 0.05 and P < 0.001, respectively, Fig. 3B ). In contrast to TET1, endometrial carcinomas and lymphomas as well as the differentiated tissues, placenta and PBMCs, showed elevated or comparable levels of TET2 mRNAs in comparison with seminomas and non-seminomas (Fig. 3A,B) . The
TCam-2 and BeWo cell lines expressed high levels of TET2 and TET3 mRNAs (Fig. 3A,B) .
In contrast to TET1 expression, the results showed that elevated TET2 and TET3 mRNA levels were found not only in seminomas and non-seminomas, but also appeared in non-GCT types of tumors and in differentiated non-cancerous tissues.
Notably, expression of both TET2 and TET3 was significantly higher in seminomas in comparison with the non-seminomas (P < 0.05 and P < 0.01, respectively, Fig. S2B,C) . Importantly, TET1 mRNA levels exceeded TET2 and TET3 mRNA levels in seminomas and mixed GCTs, but not in the group of non-GCT control testes.
As in the case of TET1, seminomas showed a highly significant increase of TET2 and TET3 mRNA expression, when compared to the seminoma-matched controls. Also, the mixed GCTs displayed higher expression not only of TET1, but also of TET3 mRNA than the tumor-matched controls. In accordance with the expression of a broad spectrum of pluripotency markers in the seminomas, this type of tumors displayed the highest expression of TET1, as well as TET2 and TET3 dioxygenases in comparison with the nonseminomas.
| Absence of IDH1 or IDH2 mutations in seminomas
Specific IDH mutations (IDH1R132, IDH2R140, or IDH2R172) have been described in tumors where aberrant production of 2-hydroxyglutarate inhibits the TET enzymes. 27, 51 Therefore, the effect of TET overexpression could be neutralized by IDH mutations. To exclude this possibility, we examined the presence of most common IDH1/2 mutations in selected seminomas of our set (T1-T4 in Supplementary   Table S2 ). We did not find any of the mutations in either of the IDH genes in four analyzed seminoma samples. These results suggest that the enzymatic function of the highly expressed TET members in the analyzed seminomas is not inhibited by 2-hydroxyglutarate.
| DNMT expression in seminomas and mixed GCTs
The levels of cytosine modifications in the genome are dependent on the activity of both TET and DNMT genes. To assess the maintenance and de novo DNA methylation capacity, we investigated expression of the DNMT1 and DNMT3A, DNMT3B
genes, respectively, in selected GCT samples. In general, expression of all DNMTs was low in the analyzed samples. We found similar mRNA levels of DNMT1 in GCTs and tumormatched controls or non-GCT controls ( Supplementary Fig. S5 ).
DNMT3B expression was higher in seminomas than in the seminoma-matched controls (P < 0.05, Fig. 4A ). Interestingly, the two non-seminoma samples with elevated levels of DNMT3B mRNA represented the two pure embryonal carcinomas analyzed | 1843 in our study (T44 and T45 in Table S2 ). The mRNA levels of DNMT3A were significantly higher in both seminomas and nonseminomas in comparison with the respective tumor-matched controls (P < 0.05 and P < 0.01, respectively, Fig. 4B ). Furthermore, the mRNA levels of DNMT3A were significantly higher in seminomas than in non-seminomas (P < 0.05) and in non-GCT controls (P < 0.05, Fig. 4B ).
Our results show elevated expression of DNMT3A and DNMT3B, but not DNMT1 in the seminomas.
| Low global levels of 5mC and 5hmC in seminomas
TET enzymes catalyze DNA demethylation by converting the existing 5mC to 5hmC. To analyze the effect of TET enzymes on the seminoma epigenome, we measured the global content of 5mC and 5hmC in genomic DNA using the liquid chromatography-mass spectrometry technique (LC/MS). Genomic DNA was isolated from the biopsies containing both germ and differentiated somatic cells. We analyzed displayed relatively high levels of the 5mC, but low levels of 5hmC (Fig. 5A,B) . The same was true for TCam-2, BeWo and HeLa cell lines (Fig. 5A,B) . Differentiated placental tissue exhibited high levels of 5mC and moderate levels of 5hmC (Fig. 5A,B) .
Importantly, we found the genome of seminomas to be hypomethylated in comparison with the seminoma-matched controls (median 1.5% and 3.5% of dG, respectively, Fig. 5A ). On the other hand, global 5mC levels of mixed GCTs (median 2.2% of dG) were not significantly different from mixed GCT-matched controls (median 3.1% of dG), also due to the lower methylation of mixed GCT-matched controls in comparison with the seminoma-matched controls (Fig. 5A) . Interestingly, two mixed GCTs that did not contain the seminoma component (T40 and T42 in Supplementary Table S2 ) had the highest 5mC levels among the mixed GCTs analyzed (Supplementary Fig. S6 ).
Both seminomas and non-seminomas displayed lower global 5hmC levels in comparison with respective matched controls (Fig. 5B) .
The important 5hmC levels in all tumor-matched controls were in accordance with the relatively high levels of 5mC, the precursor of 5hmC, in these samples (Fig. 5A ). In accordance with the low global levels of 5mC, we detected very low levels of global 5hmC in the analyzed seminomas (median 0.02% of dG, Fig. 5B ). The levels of 5hmC in non-seminomas (median 0.08% of dG) were higher in comparison with seminomas (Fig. 5B) .
Thus, we demonstrated low levels of 5mC, and consequently also 5hmC in the genome of seminomas. Interestingly, the two mixed GCTs without seminoma component displayed the highest 5mC and 5hmC levels among the analyzed non-seminoma samples (Fig. S6 ).
| IHC analysis of 5hmC
To further investigate the 5hmC levels in the GCTs and to confirm the decreased levels of 5hmC in seminomas, we performed IHC staining with anti-5hmC antibody. We were able to identify strong 5hmC nuclear signal only in Sertoli cells during normal spermatogenesis. We also demonstrated weak to negative staining intensities of GCNIS (GCNIS indicated by an arrow, Fig. 6A ).
We detected weak or negative 5hmC staining in seven out of eight analyzed seminoma samples (T1, T2, T3, T7, T10, T15, T18 in   Supplementary Table S2 ) and moderate staining intensity in one seminoma sample (T22, representative microphotographs in Fig. 6B,C and Supplementary Table S4 ). On the other hand, four analyzed samples of the mixed GCTs (T34, T40, T41, T42) displayed moderate to strong 5hmC positivity in different components, while tumormatched controls showed weaker or comparable 5hmC staining ( Supplementary Fig. S7A,B) . Intriguingly, the seminomatous components of the mixed GCTs displayed highly variable intensity of 5hmC Table S4 ) with weaker positivity detected in the tumor-matched control (representative microphotographs of T43 in Fig. 6D ). The analyzed sample of yolk sac tumor (T47) displayed moderate 5hmC positivity ( Fig. 6E and Supplementary Table S4 ). In one analyzed lymphoma sample (T55), we found weak intensities of 5hmC staining ( Supplementary Fig. S8 ). In accordance with the analysis of global 5hmC levels, our results
showed that seminomas displayed lower levels of 5hmC than the seminoma-matched controls. On the other hand, mixed GCTs displayed elevated levels of 5hmC when compared with the tumormatched controls, as was revealed by means of IHC analysis.
Importantly, the difference between the levels of 5hmC between the seminomas and non-seminomas was significant (P < 0.01, Supplementary Fig. S9 ).
The described levels of 5hmC in seminomas concerned only the cancer cells and not the lymphoid infiltrate. The lymphocytes infiltrating seminomas were evaluated separately, and unlike seminomatous tumor cells, we found high levels of 5hmC in the nuclei of lymphoid cells (representative microphotographs in Fig. 6C ).
3.9 | TET1 knockdown decreases the global 5hmC level but has no pronounced effect on the 5mC level 
| DISCUSSION
Germ cell tumors (GCTs), either seminomas or non-seminomas, 47 are malignant derivatives of GCNIS, which in turn originate from the embryonic germ cell lineage at the stage of primordial germinal cell (PGC) or gonocyte (Fig. 8) . Both precursors are characterized by expression of PGC and pluripotent cell markers 35, 39 and by epigenetic features, typically DNA hypomethylation and low levels of H3K9 trimethylation. 32, 52 Whereas, seminoma stems directly from GCNIS, the non-seminoma, specifically embryonal carcinoma is believed to require further reprograming of GCNIS (Fig. 8) . Alternatively, embryonal carcinoma can arise after reprograming of already developed seminoma cells (Fig. 8) . There are important differences between seminomas and non-seminomas as to the aggressiveness, prognosis, and treatment response, which complicates the therapy of mixed GCTs, often containing both components. 53 Finding new lineage-specific and highly sensitive markers discriminating between the seminoma and nonseminoma components in mixed GCT is thus highly desirable.
In our work, we demonstrated that most GCTs, both seminomas and non-seminomas have significantly increased levels of TET1, TET2, and TET3 mRNAs. Moreover, expression of TET1 mRNA in seminomas was higher than in non-seminomas. Expression of TET2 and TET3
mRNA was lower than that of TET1; nevertheless, TET2 and TET3
could significantly contribute to increased TET activity in GCTs in alignment with higher observed 5hmC levels. An intrinsic assay for the total TET enzymatic activity in seminomas and non-seminomas should be applied in further research. Our investigation of the DNA demethylation activity of TET enzymes revealed decreased levels of 5mC in genomic DNA of seminomas in comparison to controls. The concurrent low levels of 5hmC in seminomas are less intuitive, but the decreased availability of 5mC as a substrate for the conversion to 5hmC could potentially explain this finding. Furthermore, TET enzymes catalyze the progressive conversion of 5hmC to 5fC, 5caC, finally yielding unmodified C through the action of the base excision DNA repair pathway. 18 Consequently, the observed steady state of genomic cytosine modifications is a result of complex modification dynamics. In contrast to seminomas, we detected significant levels of 5hmC in the genomic DNA of non-seminomas. This is potentially linked with the higher global 5mC content in these tumors or, alternatively, due to the not yet fully understood dynamics of the DNA modifications discussed above.
The dynamics of 5mC and 5hmC is further complicated by the concurrent DNMT-mediated 5mC formation. Our results confirm the previously reported overexpression of DNMT3A in GCTs driven probably by depletion of miR199a-3P, a suppressor of DNMT3A. 54 Up-regulation of DNMT3B was demonstrated to initiate embryonal carcinoma-like epigenetic remodeling. 55 In accordance, we detected the highest DNMT3B overexpression in two pure embryonal carcinomas. It is difficult to predict the outcome of the DNMT-TET interplay; however, examinations of GCTs mostly show hypomethylated state of DNA in seminomas and GCNIS and low levels of 5hmC in DNA of GCNIS. 30, 32 Previous works have also compared the levels of DNA methylation in undifferentiated seminomas and GCNIS on the one hand with more differentiated non-seminoma GCTs on the other hand. The non-seminomas manifested higher global 5mC levels. 31, 32, 36 We also observed higher 5mC levels in the nonseminoma DNA. This difference may be a part of more complex epigenetic reprograming from GCNIS to non-seminoma GCT.
Multiple genes have been shown to be either up-or downregulated during this reprograming, [55] [56] [57] Fig. S10A ).
Microarray data from Oncomine database originating from a GCT cohort [58] [59] [60] show the increased expression of TET enzymes (particularly TET1) in GCTs compared with the normal testes. The highest TET1 mRNA signal was detected in seminomas, but TET1 was also overexpressed in embryonal carcinoma, mixed GCT, and yolk sac tumor (Fig. S10B ). TET2 and TET3 were slightly overexpressed in seminoma, embryonal carcinoma, mixed GCT, and yolk sac tumor (Fig. S10B) . DNMT1 was not overexpressed in any type of GCTs;
DNMT3A was slightly overexpressed in all types of GCTs (Fig. S10B) .
DNMT3B was most overexpressed in embryonal carcinoma while only slightly overexpressed in seminoma (Fig. S10B ).
To bring new insight into the relationship of TET expression intensity and 5hmC levels, we performed depletion of TET1 in the seminoma-derived TCam-2 cell line. Importantly, TET1 was shown to be substantially overexpressed in TCam-2, 31 and our qRT-PCR assays confirmed this result. Furthermore, TET1 mRNA expression was shown to be dependent on the cell density in this cell line. Importantly, the increase in the TET1 mRNA levels was not accompanied by growth of the genomic 5hmC levels in TCam-2. 31 Nevertheless, the 5hmC levels do increase after TCam-2 transition into EC-like state. 31 Particularly, IDH1 R132 and IDH2 R172 mutations were not detected in the TCam-2 cell line. 31 We have shown in this work that a further decrease of genomic 5hmC content in the TCam-2 cell line after TET1 mRNA depletion is possible. We can presume that the increase of The overall hypomethylated status of seminomas is also reflected by the activity of the mobile elements in the genome. Human endogenous retroviruses of type K (HERV-K) are efficiently transcribed in GCTs, 61, 62 and inducible expression of the HERV-K rec gene in the mouse was shown to disturb germ cell development and recapitulate the GCNIS. 63 Also HERV-W expression, including the syncytin-1-encoding HERVWE1 copy, has been detected in GCTs, 62, 64 which is particularly interesting given that syncytin-1 expression is tightly suppressed in non-placental tissues. 65 Hypomethylation correlates with L1 retrotransposon expression and somatic retrotransposition activity was demonstrated in cancer genomes. 66 Last but not least, there is the question of the identity of TET-and hmC-positive cells present in healthy testicular tissue of non-GCT controls. We observed weaker TET1 signal in germ line cells at the basal membrane and retained signal in the lumen of the tubules.
Furthermore, Sertolli cells in the tubules and to some extent Leydig cells in the interstitium were weakly positive for TET1 ( Fig. 2A) . The IHC staining for 5hmC showed intense staining of Sertoli cells and decreasing signal from the basal lamina to the lumen of tubules in accordance with previous results of in accordance with previous results of Nettersheim et al. (2013) . 31 The lower signal in seminomas in comparison with non-seminoma GCTs reflects the low rate of 5hmC-positive cells; the staining intensity of individual cells is similar (Fig. 6A) .
Therefore, further studies will require more precise correlation of TETand 5hmC-positive cells in GCTs with distinct stages of germ line cells in healthy testicular tissue. It should also be noted that the non-GCT control tissues we examined were derived from the patients of higher age (median 45 years, Supplementary Table S2 ) with spermatogenic epithelium affected by age-dependent changes.
Our results confirmed the expression of pluripotent markers OCT4, NANOG, and SALL4 in seminomas and non-seminoma GCTs (Supplementary Fig. S1A -C), with the exception of teratomas (data not shown). This agrees with previous demonstration of pluripotent marker expression in GCTs (excluding teratoma) and in PGCs/ gonocytes. These markers include highly expressed embryonic factors involved in the pluripotency maintenance, including OCT4 and NANOG, 67 and transcription factor SALL4. 44 The highest levels of pluripotent marker expression in seminomas further underlines the germ cell origin of the seminomas and stresses out the reprograming occurring during the transition to non-seminomas.
In conclusion, we have described elevated expression of TET dioxygenases in GCTs, particularly the expression of TET1 in seminomas that are concurrent with the very low levels of genomic 5mC and 5hmC. These findings improve our understanding of the epigenetic landscape in GCTs and add TET1 to the list of pluripotent cell markers present in seminomas and non-seminoma GCTs. In general, we propose that highly elevated expression of TET enzymes might facilitate maintenance of the low DNA methylation level in seminoma, thus preventing its further reprograming and differentiation (Fig. 8) . Pure seminomas maintain the epigenetic features of precursor pluripotent germ cells, which are in direct contrast to the CIMP of certain other tumor types. Low levels of genomic 5mC and 5hmC, high expression of TET1 dioxygenase, intact IDH1/2 activity, expression of pluripotency markers, and derepression of mobile elements are the hallmarks of a complex that we suggest to be denoted as an "antimethylator" phenotype. Programme.
